• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2加强疫苗接种后骨髓瘤患者中变异抗体的差异及混合免疫的影响

Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.

作者信息

Moreno Alberto, Manning Kelly, Azeem Maryam I, Nooka Ajay K, Ellis Madison, Manalo Renee Julia, Switchenko Jeffrey M, Wali Bushra, Kaufman Jonathan L, Hofmeister Craig C, Joseph Nisha S, Lonial Sagar, Dhodapkar Kavita M, Dhodapkar Madhav V, Suthar Mehul S

机构信息

Emory Vaccine Center, Emory University, Atlanta, Georgia.

Emory National Primate Research Center, Atlanta, Georgia.

出版信息

NPJ Vaccines. 2024 Oct 27;9(1):201. doi: 10.1038/s41541-024-00999-6.

DOI:10.1038/s41541-024-00999-6
PMID:39465249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11514147/
Abstract

Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.

摘要

血液系统恶性肿瘤与感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)期间并发症风险增加相关。单价或二价加强疫苗可降低多发性骨髓瘤患者的疾病严重程度、住院率和死亡率。我们对多发性骨髓瘤(MM)患者接种单价(WA1)或二价(WA1/BA.5)SARS-CoV-2加强疫苗后的病毒中和及刺突结合抗体谱进行了特征分析。二价疫苗接种改善了结合抗体的广度,但对当代变体的中和活性没有改善。混合免疫和免疫印记会影响疫苗诱导的免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c59/11514147/70ce85c401f4/41541_2024_999_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c59/11514147/036de52d06e0/41541_2024_999_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c59/11514147/70ce85c401f4/41541_2024_999_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c59/11514147/036de52d06e0/41541_2024_999_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c59/11514147/70ce85c401f4/41541_2024_999_Fig2_HTML.jpg

相似文献

1
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.SARS-CoV-2加强疫苗接种后骨髓瘤患者中变异抗体的差异及混合免疫的影响
NPJ Vaccines. 2024 Oct 27;9(1):201. doi: 10.1038/s41541-024-00999-6.
2
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.多发性骨髓瘤患者接种SARS-CoV-2加强疫苗后变异体结合/中和抗体的差异:混合免疫的影响
bioRxiv. 2023 Aug 22:2023.08.17.553767. doi: 10.1101/2023.08.17.553767.
3
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.骨髓瘤患者接种SARS-CoV-2加强疫苗后变异体结合/中和抗体的差异:混合免疫的影响
Res Sq. 2023 Sep 21:rs.3.rs-3293339. doi: 10.21203/rs.3.rs-3293339/v1.
4
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.多元化的体液免疫和加强疫苗的影响:初次或第二次加强针前后 SARS-CoV-2 抗体特征和奥密克戎 BA.2 的中和作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0060524. doi: 10.1128/spectrum.00605-24. Epub 2024 Aug 20.
5
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.增强对奥密克戎亚谱系的中和作用:二价和单价 COVID-19 加强疫苗以及最近 SARS-CoV-2 奥密克戎变异株感染的相关见解。
Influenza Other Respir Viruses. 2024 Oct;18(10):e70000. doi: 10.1111/irv.70000.
6
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.比较携带早期和晚期 SARS-CoV-2 变异株刺突的单价和双价腺病毒疫苗的免疫原性。
Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19.
7
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.暴露于 BA.4/5 蛋白可导致疫苗接种者体内对奥密克戎 BA.1、BA.2、BA.2.12.1 和 BA.4/5 的中和作用。
Sci Immunol. 2022 Dec 23;7(78):eade9888. doi: 10.1126/sciimmunol.ade9888.
8
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.SARS-CoV-2 BA.4/5 感染在混合免疫背景下比 BA.1 引发更多的交叉反应性 FcγRIIIa 信号传导和中和作用。
J Virol. 2024 Jul 23;98(7):e0067824. doi: 10.1128/jvi.00678-24. Epub 2024 Jul 2.
9
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.与多发性骨髓瘤患者对 SARS-CoV-2 二价加强疫苗免疫反应欠佳相关的细胞机制。
EBioMedicine. 2023 Dec;98:104886. doi: 10.1016/j.ebiom.2023.104886. Epub 2023 Nov 22.
10
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛,2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.

引用本文的文献

1
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients.多发性骨髓瘤患者接种第三剂严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗后的体液和细胞免疫反应随访
Front Immunol. 2025 Feb 18;16:1532947. doi: 10.3389/fimmu.2025.1532947. eCollection 2025.

本文引用的文献

1
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.接种SARS-CoV-2疫苗的多发性骨髓瘤患者中的突破性感染改善了对奥密克戎变种的交叉保护。
Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518.
2
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.与多发性骨髓瘤患者对 SARS-CoV-2 二价加强疫苗免疫反应欠佳相关的细胞机制。
EBioMedicine. 2023 Dec;98:104886. doi: 10.1016/j.ebiom.2023.104886. Epub 2023 Nov 22.
3
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
接种过 B 细胞恶性肿瘤患者的加强针后,针对活 SARS-CoV-2 变体(包括 BA.4/5)的抗体结合和中和作用。
Cancer Res Commun. 2022 Dec;2(12):1684-1692. doi: 10.1158/2767-9764.crc-22-0471.
4
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.来自mRNA二价加强针的针对BA.2.75.2、BQ.1.1和XBB的中和作用。
N Engl J Med. 2023 Jan 12;388(2):183-185. doi: 10.1056/NEJMc2214293. Epub 2022 Dec 21.
5
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.多发性骨髓瘤患者接种 3 剂 mRNA 疫苗后对 SARS-CoV-2 变异体的中和能力和 CD8+ T 细胞反应受损:与突破性感染的相关性。
Blood Cancer Discov. 2023 Mar 1;4(2):106-117. doi: 10.1158/2643-3230.BCD-22-0173.
6
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.血液恶性肿瘤患者的长程和持续性 COVID-19:从基础到临床。
Curr Opin Infect Dis. 2022 Aug 1;35(4):271-279. doi: 10.1097/QCO.0000000000000841. Epub 2022 Jul 5.
7
Immune boosting by B.1.1.529 Omicron) depends on previous SARS-CoV-2 exposure.免疫增强作用取决于先前的 SARS-CoV-2 暴露情况。
Science. 2022 Jul 15;377(6603):eabq1841. doi: 10.1126/science.abq1841.
8
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.骨髓瘤患者接种 SARS-CoV-2 疫苗后中和抗体反应的决定因素。
J Clin Oncol. 2022 Sep 10;40(26):3057-3064. doi: 10.1200/JCO.21.02257. Epub 2022 Mar 8.
9
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.mRNA-1273 和 BNT162b2 mRNA 疫苗对 SARS-CoV-2 奥密克戎变异株的中和活性降低。
Cell Rep Med. 2022 Jan 24;3(2):100529. doi: 10.1016/j.xcrm.2022.100529. eCollection 2022 Feb 15.
10
A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG.一种新型多重电化学发光免疫分析方法,用于检测和定量抗 SARS-CoV-2 IgG 和抗季节性地方性人类冠状病毒 IgG。
J Clin Virol. 2022 Jan;146:105050. doi: 10.1016/j.jcv.2021.105050. Epub 2021 Dec 1.